Immunotech Biopharm Ltd’s Rights Issue Oversubscribed, Raising HK$257.29 Million
I'm PortAI, I can summarize articles.
Immunotech Biopharm Ltd has successfully completed its rights issue, raising approximately HK$257.29 million, with net proceeds estimated at HK$251.88 million. The oversubscription reflects strong investor confidence, which may enhance the company's financial position and operational capabilities. Immunotech Biopharm Ltd operates in the biopharmaceutical industry, focusing on innovative healthcare solutions, and has a current market cap of HK$2.03 billion.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments